Remove Dermatology Remove Packaging Remove Scientist
article thumbnail

Topical products: Aiming for quality, simplicity, and cost-efficiency in their development, scale-up, and manufacturing

Pharmaceutical Technology

It requires having access to proper techniques and skill sets, state-of-the-art equipment, process scientists and engineers who have a deep understanding of Quality by Design (QbD) principles, and methods for product and process characterisation. Expertise in analytical testing, validation, and quality control are also essential.

article thumbnail

Consumer health innovation – where passion and science meet

pharmaphorum

Heather Barnes, external innovation lead EMEA at Johnson and Johnson Consumer Health, is a scientist who is truly passionate about consumer health. With her background in biochemistry and eye for identifying innovation trends, the future is bright at Johnson & Johnson Innovation. Self care, skin health and technology innovation.

Allergies 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

2) Paxlovid (nirmatrelvir/ritonavir) Paxlovid is a dual-packaged oral medication for the treatment of COVID-19. a month for either 150 mg or 300 mg dose strength packages, and $3,462.13 for the 75 mg dose strength package in January 2023, according to the manufacturer. for a 2-pen package (0.6 for the 3-pen package (1.8

Sales 98
article thumbnail

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients

The Pharma Data

Discovered and developed by AbbVie scientists, RINVOQ is an oral, once daily, selective and reversible JAK inhibitor studied in several immune-mediated inflammatory diseases. European Academy of Dermatology and Venerology Congress. RINVOQ (upadacitinib) [Package Insert]. About Upadacitinib (RINVOQ). Available at: [link].